59.99
price up icon1.64%   0.97
pre-market  Vorhandelsmarkt:  60.11   0.12   +0.20%
loading
Schlusskurs vom Vortag:
$59.02
Offen:
$59.35
24-Stunden-Volumen:
1.09M
Relative Volume:
0.43
Marktkapitalisierung:
$7.39B
Einnahmen:
$947.36M
Nettoeinkommen (Verlust:
$392.47M
KGV:
19.86
EPS:
3.02
Netto-Cashflow:
$392.71M
1W Leistung:
+3.91%
1M Leistung:
+11.09%
6M Leistung:
+5.67%
1J Leistung:
+10.91%
1-Tages-Spanne:
Value
$58.67
$60.07
1-Wochen-Bereich:
Value
$57.67
$61.75
52-Wochen-Spanne:
Value
$42.01
$70.50

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name
Firmenname
Halozyme Therapeutics Inc
Name
Telefon
(858) 794-8889
Name
Adresse
12390 EL CAMINO REAL, SAN DIEGO, CA
Name
Mitarbeiter
350
Name
Twitter
@halozymeinc
Name
Nächster Verdiensttermin
2025-02-18
Name
Neueste SEC-Einreichungen
Name
HALO's Discussions on Twitter

Vergleichen Sie HALO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
HALO
Halozyme Therapeutics Inc
59.99 7.27B 947.36M 392.47M 392.71M 3.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 118.67B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.54 59.23B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
419.56 52.67B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
690.32 41.24B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
304.30 32.36B 3.81B -644.79M -669.77M -6.24

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-10 Fortgesetzt Goldman Neutral
2025-05-14 Herabstufung Morgan Stanley Overweight → Equal-Weight
2025-05-13 Herabstufung Leerink Partners Market Perform → Underperform
2024-10-07 Herabstufung Wells Fargo Overweight → Equal Weight
2024-09-19 Herabstufung JP Morgan Overweight → Neutral
2024-06-07 Herabstufung Piper Sandler Overweight → Neutral
2024-02-29 Eingeleitet TD Cowen Outperform
2023-07-24 Herabstufung Goldman Buy → Neutral
2023-07-24 Eingeleitet H.C. Wainwright Buy
2023-05-10 Hochstufung Piper Sandler Neutral → Overweight
2023-03-27 Fortgesetzt Berenberg Buy
2023-03-16 Herabstufung SVB Securities Outperform → Market Perform
2022-12-21 Fortgesetzt Morgan Stanley Overweight
2022-11-28 Eingeleitet Wells Fargo Overweight
2022-09-09 Eingeleitet Morgan Stanley Overweight
2022-05-23 Eingeleitet SVB Leerink Outperform
2021-06-14 Eingeleitet Evercore ISI Outperform
2021-05-17 Eingeleitet SVB Leerink Outperform
2021-05-11 Herabstufung Piper Sandler Overweight → Neutral
2021-01-21 Bestätigt The Benchmark Company Buy
2020-12-17 Eingeleitet Berenberg Buy
2020-09-14 Fortgesetzt JP Morgan Overweight
2020-07-01 Eingeleitet The Benchmark Company Buy
2020-02-05 Hochstufung Piper Sandler Neutral → Overweight
2020-01-09 Hochstufung BMO Capital Markets Market Perform → Outperform
2020-01-08 Eingeleitet Goldman Buy
2019-11-05 Hochstufung Barclays Underweight → Equal Weight
2018-10-19 Fortgesetzt Piper Jaffray Neutral
2018-05-11 Herabstufung Barclays Equal Weight → Underweight
2018-01-24 Eingeleitet Goldman Neutral
2017-10-16 Bestätigt Piper Jaffray Overweight
2017-01-06 Herabstufung Citigroup Buy → Neutral
2016-11-03 Eingeleitet Deutsche Bank Buy
2015-12-04 Eingeleitet Wells Fargo Outperform
2015-11-18 Eingeleitet Citigroup Buy
2015-09-22 Eingeleitet Barclays Overweight
2015-06-22 Bestätigt JP Morgan Overweight
2015-03-03 Bestätigt UBS Buy
2015-02-18 Bestätigt MLV & Co Buy
2015-01-08 Bestätigt MLV & Co Buy
Alle ansehen

Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten

pulisher
Aug 04, 2025

Earnings Outlook For Halozyme Therapeutics - 富途牛牛

Aug 04, 2025
pulisher
Aug 03, 2025

What makes Halozyme Therapeutics Inc. stock price move sharplyMarket-beating returns - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Halozyme Therapeutics Inc. Stock Analysis and ForecastTremendous growth potential - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Does Halozyme Therapeutics Inc. stock perform well during market downturnsBuild a portfolio that withstands market volatility - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What catalysts could drive Halozyme Therapeutics Inc. stock higher in 2025Fastest-growing stock picks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What analysts say about Halozyme Therapeutics Inc. stockDiscover stock picks with superior returns - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What institutional investors are buying Halozyme Therapeutics Inc. stockDiscover market opportunities with real-time data - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Halozyme Therapeutics Inc. stock overvalued or undervaluedExceptional growth trajectory - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How many analysts rate Halozyme Therapeutics Inc. as a “Buy”Track top-performing stocks effortlessly - Jammu Links News

Aug 03, 2025
pulisher
Jul 31, 2025

Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN

Jul 31, 2025
pulisher
Jul 30, 2025

Halozyme Therapeutics Insider Lowered Holding By 38% During Last Year - 富途牛牛

Jul 30, 2025
pulisher
Jul 30, 2025

Morgan Stanley Maintains a Hold on Halozyme Therapeutics (HALO) With a $62 PT - MSN

Jul 30, 2025
pulisher
Jul 29, 2025

A Quick Look at Today's Ratings for Halozyme Therapeutics(HALO.US), With a Forecast Between $47 to $79 - 富途牛牛

Jul 29, 2025
pulisher
Jul 29, 2025

How Halozyme Therapeutics Inc. stock performs during market volatilitySmart Money Tracking Signal Generator Activated - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Short Interest Drops in Halozyme Therapeutics Inc. After RallyOversold Recovery Opportunity Stocks Attract Buyers - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Jul 29, 2025
pulisher
Jul 29, 2025

Halozyme Therapeutics Inc. Outperforms Peers on Volume MetricsPrice Action Based Buy Opportunity List Published - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

Why Halozyme Therapeutics Inc. stock attracts strong analyst attentionProfit Target Stock Opportunity Monitor Activated - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

How Resilient Is Halozyme Therapeutics Inc. Stock During Economic DownturnsMarket Entry and Exit Point Tips From Traders - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Published on: 2025-07-28 01:53:45 - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

What is Halozyme Therapeutics Inc. company’s growth strategyOutstanding capital returns - Jammu Links News

Jul 27, 2025
pulisher
Jul 25, 2025

Halozyme’s Promising Cancer Study: A Potential Game-Changer in Oncology - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

Should I buy Halozyme Therapeutics Inc. stock before earningsRecord-setting profit potential - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

What risks could impact Halozyme Therapeutics Inc. stock performanceConsistently superior profits - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

38% Of This Halozyme Therapeutics Insider's Holdings Were Sold - simplywall.st

Jul 24, 2025
pulisher
Jul 24, 2025

Is Halozyme Therapeutics Inc. stock overhyped or has real potentialBreakout profit opportunities - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Halozyme to Report Second Quarter 2025 Financial and Operating Results - Eastern Progress

Jul 24, 2025
pulisher
Jul 23, 2025

BlackRock, Inc. Adjusts Holdings in Halozyme Therapeutics Inc. - GuruFocus

Jul 23, 2025
pulisher
Jul 23, 2025

Halozyme Therapeutics Says Myeloma Drug With Enhanze Delivery Technology Gets EU Approval - 富途牛牛

Jul 23, 2025
pulisher
Jul 23, 2025

Is Halozyme Therapeutics Inc. a good long term investmentFree Risk Assessment Services - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

J&J Darzalex injectable cleared in EU for smouldering MM (JNJ) - Seeking Alpha

Jul 23, 2025
pulisher
Jul 23, 2025

Halozyme says EU approves new indication for Janssen’s Darzalex Faspro - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma - WV News

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Halozyme Therapeutics Inc. stock priceFree Stock Market Real-Time Monitoring - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again - Yahoo Finance

Jul 22, 2025

Finanzdaten der Halozyme Therapeutics Inc-Aktie (HALO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$78.04
price up icon 3.24%
$37.88
price up icon 2.07%
$111.24
price up icon 2.35%
$29.32
price up icon 8.31%
$110.03
price up icon 2.51%
biotechnology ONC
$304.30
price up icon 1.77%
Kapitalisierung:     |  Volumen (24h):